Page 36 - ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் Today - Breaking & Trending Today

Genocea to Present Novel Preclinical Inhibigen™ Data at AACR Annual Meeting 2021


Share:
Insights into Inhibigen biology may yield new therapeutic targets to address immunotherapy resistance
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presented preclinical data that offers new insights into Inhibigen™-associated responses and continues to underscore the detrimental impact of their inclusion in cancer immunotherapies at the American Association for Cancer Research (AACR) Annual Meeting 2021 from April 10-15. The findings – powered by Genocea s proprietary ATLAS™ platform – further validate previous research presented at SITC 2020 and published in
Cancer Discovery, together revealing that the presence of an Inhibigen (antigen uniquely identifiable by ATLAS as dampening anti-tumor immune responses) in an otherwise protective immunotherapy can completely reverse the therapy s intended anti-tumor response ....

United Kingdom , United States , Jessica Baker Flechtner , Hanna Starobinets , Sarah Oconnell , Genocea Biosciences , Clinical Research Excluding Trials , American Association For Cancer Research , Genocea Biosciences Inc , American Association , Cancer Research , Annual Meeting , Cancer Discovery , Chief Scientific Officer , Clinical Research Excluding , Private Securities Litigation Reform , Annual Report , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் , சாரா ஒக்கொண்னேழில் , அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி , அமெரிக்கன் சங்கம் , புற்றுநோய் ஆராய்ச்சி , ஆண்டு சந்தித்தல் , புற்றுநோய் கண்டுபிடிப்பு , தலைமை அறிவியல் அதிகாரி ,

SEC Warns SPAC Backers They Can't Bypass Securities Laws


by Tyler Durden
Friday, Apr 09, 2021 - 11:01 AM
As we noted earlier this week, it appears the days of SPACs debuting a dozen at a time, what many had speculated might be the peak of SPAC-mania, are over. Only a handful of new deals hit public markets this week.
On Friday morning, the FT reported that one reason for the slowdown appears to be a declining appetite for institutional financing from institutional investors like Fidelity and Wellington Management, which have poured billions of dollars into so-called PIPE vehicles, a critical aspect of SPAC dealmaking.
SPACs raise money from public markets during their debut, but getting a deal done typically requires an infusion of private capital, often from a variety of sources. ....

United States , New Zealand General , New Zealand , United Kingdom , Richard Brandon , Gary Gensler , Chamath Palihapitiya , John Coates , Exchange Commission , Virgin Galactic , Exchange Act Section , Division Of Corporation , Purpose Acquisition Companies , Securities Exchange , Wellington Management , Special Purpose Acquisition Companies , Corporation Finance , Exchange Act , Private Securities Litigation Reform Act , Securities Act , Securities Act Section , Private Securities Litigation Reform , Securities Exchange Act , ஒன்றுபட்டது மாநிலங்களில் , புதியது ஜீலாந்து ஜநரல் , புதியது ஜீலாந்து ,

SPACs, IPOs And Liability Risk Under The Securities Laws: John Coates, SEC, Acting Director, Division Of Corporation Finance, April 8, 2021


SPACs, IPOs And Liability Risk Under The Securities Laws: John Coates, SEC, Acting Director, Division Of Corporation Finance, April 8, 2021
Date
08/04/2021
Over the past six months, the U.S. securities markets have seen an unprecedented surge in the use and popularity of Special Purpose Acquisition Companies (or SPACs).[1],[2] Shareholder advocates – as well as business journalists and legal and banking practitioners, and even SPAC enthusiasts themselves[3] – are sounding alarms about the surge. Concerns include risks from fees, conflicts, and sponsor compensation, from celebrity sponsorship and the potential for retail participation drawn by baseless hype, and the sheer amount of capital pouring into the SPACs, each of which is designed to hunt for a private target to take public.[4] With the unprecedented surge has come unprecedented scrutiny, and new issues with both standard and innovative SPAC structures keep surfacing. ....

United States , Exchange Commission , Exchange Act Section , Division Of Corporation , Purpose Acquisition Companies , Securities Exchange , Special Purpose Acquisition Companies , Corporation Finance , Exchange Act , Private Securities Litigation Reform Act , Securities Act , Securities Act Section , Private Securities Litigation Reform , Securities Exchange Act , ஒன்றுபட்டது மாநிலங்களில் , பரிமாற்றம் தரகு , பரிமாற்றம் நாடகம் பிரிவு , பிரிவு ஆஃப் நிறுவனம் , நோக்கம் கையகப்படுத்தல் நிறுவனங்கள் , பத்திரங்கள் பரிமாற்றம் , சிறப்பு நோக்கம் கையகப்படுத்தல் நிறுவனங்கள் , நிறுவனம் நிதி , பரிமாற்றம் நாடகம் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , பத்திரங்கள் நாடகம் , பத்திரங்கள் நாடகம் பிரிவு ,